

Rockwell Medical Enters into Exclusive License Agreement with Jeil for the Rights to Commercialize Triferic® in South Korea

Torreya advised Rockwell Medical on the transaction

Wixom, Michigan and Seoul, South Korea, September 9, 2020

Rockwell Medical, Inc. (Nasdaq: RMTI; "Rockwell Medical"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced it entered into an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. ("Jeil"), for the rights to commercialize Triferic® (ferric pyrophosphate citrate) in South Korea.

Under the terms of the license agreement, Jeil will be the exclusive development and commercialization partner for Triferic® in South Korea and Rockwell Medical will supply the product to Jeil. In consideration for the license, Rockwell Medical will receive an upfront fee and will be eligible for milestone payments and royalties on net sales.

Under the terms of the agreement, Jeil will be the exclusive development and commercialization partner for Triferic® in South Korea and Rockwell Medical will supply the product to Jeil. In consideration for the license, Rockwell Medical will receive an upfront fee, and will be eligible for milestone payments and royalties on net sales. Jeil will leverage its strong development and commercialization capabilities and local market expertise to promote Triferic® to nephrologists in South Korea. A Joint Alliance Committee, comprised of members from Rockwell Medical and Jeil, will guide the development and execution for Triferic in South Korea. Jeil will be responsible for all regulatory and commercialization activities. Product sales are anticipated to begin in early 2022, subject to regulatory approval.

Torreya advised Rockwell Medical on this transaction, highlighting Torreya's commitment in cross-border transactions. Since the beginning of the year, Torreya has advised on almost 20 deals, over half of which were between cross-border parties.

ABOUT ROCKWELL MEDICAL, INC.:

For more information about Rockwell Medical, please see: www.rockwellmed.com

ABOUT JEIL PHARMACEUTICAL CO., LTD.:

For more information about Jeil, please see: www.jeilpharm.co.kr/english



Deal Press Release

Torreya Contact

GWEN MELNYK

Vice President | New York Office

gwen.melnyk@torreya.com | 646.671.2168 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.